Katetrizační ablace komorových tachykardií provázejících strukturní onemocnění srdce: editorial

J. Kautzner

Vnitr Lek 2006, 52(6):552-555  

Trimetazidin v léčbě stabilní anginy pectoris: editorial

J. Meluzín

Vnitr Lek 2006, 52(6):556-557  

Trimetazidin - modulátor energetického metabolizmu myokardu: editorial

F. Kölbel

Vnitr Lek 2006, 52(6):558-559  

Význam endokanabinoidního systému v modulaci kardiometabolických rizikových faktorů: editorial

T. Kvasnička

Vnitr Lek 2006, 52(6):560  

Biologická léčba revmatických onemocnění: editorial

K. Pavelka

Vnitr Lek 2006, 52(6):561-562  

Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy

L. Elbl, I. Vášová, M. Navrátil, J. Vorlíček, L. Malášková, J. Špinar

Vnitr Lek 2006, 52(6):563-570  

The study objective:The aim of the study was to find out the relationship between plasmatic levels of brain natriuretic peptide (BNP) and echocardiographic indicators of left ventricle (LV) function in patients who were in a long-term remission after the therapy of hematological malignity and examined in order to diagnose the late cardiotoxicity of doxorubicin. Methods and patient sample:We enrolled 55 patients (31 men/24 women) aged 43 ± 16 (median 41; 21-79) who were treated for historically diagnosed malignant lymphoma. At the time of examination, all patients were in a long-term remission and, at the same time,...

Obesity and progression of chronic renal insufficiency: a Czech long term prospective double-blind randomised multicentre study

V. Teplan, O. Schück, V. Hanzal, J. Hajný, M. Horáčková, M. Ryba, I. Staněk, S. Šurel, M. Bret, M. Štollová, D. Sasaková

Vnitr Lek 2006, 52(6):571-576  

Obesity represents one of serious risk factors in chronic renal failure patients (CRF). In three years prospective double-blind randomised multicentre study we monitored 66 patients with advanced chronic renal insufficiency, GFR 24.4-37.3 ml/min (0.41 to 0.62 ml/s) and BMI ≥ 30 kg/m² on long term low-protein diet (0.6 P/kg BW/day) and ACEI + ARB. Thirty four randomly selected patients (group I) were treated with keto amino acids, 32 patients in control group (group II) with placebo. During the study period significant decrease of BMI, proteinuria and slowing in progression of renal failure (C_in) were found. Significant changes...

Sustained monomorphic ventricular tachycardia in patients with structural heart disease. Different arrhythmogenic substrates, different options of palliative and curative treatment in the era of three-dimensional mapping

M. Fiala, J. Chovančík, R. Neuwirth, I. Nykl, H. Szymeczek, R. Nevřalová, O. Jiravský, M. Branny

Vnitr Lek 2006, 52(6):577-589  

Results of catheter ablation of sustained monomorphic ventricular tachycardia (SMVT) in patients with structural heart disease are presented. Methods:Catheter ablation was performed in 34 patients (5 females), aged 63 ± 11 years. One (3 %) patient had a permanent SMVT resistant to electric cardioversion, 13 (38 %) patients had incessant SMVT, 4 (12 %) patients had SMVT at least once a day, 9 (26 %) patients at least once a week, and 7 (21 %) patients at least once a month. Twenty-nine (85 %) patients were treated with amiodarone. Twenty-seven (79 %) patients had a history of remote myocardial infarction, 2 (6 %) patients...

The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy

P. Husa, P. Šlesinger, H. Štroblová, A. Svobodník

Vnitr Lek 2006, 52(6):590-595  

Today, the standard therapy of patients with chronic HCV (hepatitis C virus) infection is based on combination of pegylated interferon α (PEG-IFN) and ribavirin. The study objective:The aim of the study is to find correlations between patient's body weight, gender and baseline viral load and the efficacy of antiviral therapy in terms of achieving end-of-treatment viral response (ETVR) and sustained viral response (SVR). Methods and patient sample:We enrolled 133 patients with chronic HCV infection. All of them were treated by combination of PEG-IFN α-2a (180 μg once a week) and ribavirin. Ribavirin doses...

Prevalence and causes of reflux in deep venous system of the leg in patients with insufficiency of superficial veins

D. Musil, J. Herman

Vnitr Lek 2006, 52(6):596-601  

The aim of the prospective study was to find out the following:1.What is the prevalence of deep vein reflux of the leg in patients with superficial vein reflux detected by ultrasonography? 2. What are the possible causes of deep vein insufficiency of the leg retrospectively detectable on the basis of targeted medical history? 3. Is the incidence of identified deep vein insufficiency of the leg gender specific? The sample consisted of 100 legs with superficial vein reflux detected on ultrasonography (C1 - C4 / CEAP) of 79 randomized patients (59 women aged 45 ± 12 years and 20 men aged 52 ± 15 years). We collected...

Molecular genetic diagnostics and screening of hereditary hemochromatosis

J. Zlocha, L. Kovács, S. Požgayová, V. Kupčová, S. Durínová

Vnitr Lek 2006, 52(6):602-608  

Background:Hereditary hemochromatosis is considered one of the most common hereditary diseases in population of Caucasian origin. In recent years, a candidate gene for HLA-linked hemochromatosis, HFE, has been cloned, and a single G-to-A mutation resulting in a cysteine-to-tyrosine substitution (C282Y) has been identified in up to 80 % of study patients with type 1 hereditary hemochromatosis. The purpose of the paper was to confirm the importance of genetic testing for HFE mutations in making the diagnosis of hemochromatosis and find out a suitable diagnostic algorithm for the indication of this form of diagnostics in patients suspected...

Trimetazidine in the treatment of stable angina pectoris TRIADA - (TRImetazidine in stable Angina twice Daily)

V. Chaloupka

Vnitr Lek 2006, 52(6):609-614  

The primary objective of the national study TRIADA was to evaluate the efficacy and tolerability of Preductal MR (trimetazidine) at a dose of 35 mg twice daily which was added to current therapy involving the maximum of two antianginal drugs. The outcome was evaluated after 12 weeks of therapy and compared with baseline data. The study included 74 patients with stable exertional angina pectoris (AP) and positive exercise testing results. Trimetazidine (Preductal MR) at a dose of 35 mg twice daily was added to their current therapy involving two drugs at most. TRIADA confirmed that the use of trimetazidine in a new pharmacological form is effective...

Impact of endocannabinoid system in modulation of the metabolic syndrome

A. Šulcová

Vnitr Lek 2006, 52(6):615-618  

Endocannabinoid system, the complex of specific cannabinoid receptors (CB₁ and CB₂ subtypes) and their endogenous agonistic ligands (endocannabinoids) plays, besides others, an important role in the central and peripheral regulation of food intake, fat accumulation, and lipid and glucose metabolism. Alterations of these functions are associated with endocannabinoid system hyperactivity. The cannabinoid receptor CB₁ antagonist rimonabant normalizes the over activated endocannabinoid system which contributes to the regulation of energy homeostasis, and improves lipid and glucose metabolism - decreases body weight, waist...

Diagnostics and therapy of hepatorenal syndrome. Recommendations of of the working group on portal hypertension of the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society.

R. Brůha, K. Balihar, P. Drastich, P. Hůlek, J. Lata, J. Petrtýl, V. Procházka, J. Špičák, T. Vaňásek, M. Volfová, P. Zdeněk

Vnitr Lek 2006, 52(6):649-650  

Hepatorenal syndrome is a functional renal failure in patients with advanced cirrhosis and portal hypertension or acute liver failure. It is caused by extreme vasoconstriction in renal arterial bed. Type I HRS presents as an acute renal failure, while type II HRS is chronic alteration of renal function in patients with refractory ascites. Prognosis of HRS is very poor with survival reaching several weeks in patients with HRS type I. Causal treatment is liver transplantation, other treatment options include use of splanchnic vasoconstrictors (terlipressin) together with plasmaexpansion (albumin) and TIPS. It is important to exclude nephrotoxic medication...

Ubiquitins, proteasomes, sumoylation and application today and in future for cancer and other diseases therapy II. Sumoylation and neddylation as posttranslational modifications of proteins and their significance

O. Fuchs, R. Neuwirtová

Vnitr Lek 2006, 52(6):619-627  

Posttranslational protein modifications are effective devices that cells use to control the functions of proteins. Ubiquitin-like protein modifiers (Ubls) are posttranslationally attached to proteins by enzymatic reactions that are similar to ubiquitin conjugation. SUMO (small ubiquitin-related modifier) family proteins are the most intriguing Ubls. Sumoylation is the covalent attachment of SUMO to target proteins. Neddylation is the process that conjugates the ubiquitin-like polypeptide Nedd8 to the conserved lysines of cullins. Cullin family proteins organize ubiquitin ligase complexes to target numerous cellular proteins for polyubiquitinylation...

Nuclear receptors PPARα

V. Soška

Vnitr Lek 2006, 52(6):628-631  

Mechanism of the fibrates action is mediated by nuclear PPARα receptors (Peroxisome Proliferator-Activated Receptor). These receptors regulate a number of genes that are involved both in lipids and lipoproteins metabolism and other mediators (e.g. inflammatory mediatores). Due to PPARα activation by fibrates, triglycerides and small dense LDL concentration is decreased, HDL cholesterol is increased and both inflammation and prothrombotic status are reduced. These effects are very important in patients with metabolic syndrom.

Biological treatment of rheumatic diseases

L. Procházková, J. Böhmová, M. Souček

Vnitr Lek 2006, 52(6):632-639  

During recent two decades the progress in the understanding of the pathogenesis of the autoimmune diseases have led to new treatment targets, whose achievement claims new therapeutic advancings. Biological drugs complete or replace conventional immunosuppressive therapies in the treatment of autoimmune diseases. In the treatment of rheumatic diseases are currently used TNFα inhibitors and blockade of the IL-1, in phase of clinical trials or actual registration are agents blocking IL-6, the antibodies against B cell and inhibition of activation of T-cells by costimulating blockade with CTLA4Ig. In the Czech Republic are for treating of rheumatic...

Chronic renal disease and gravidity - case study

B. Holman, I. Bryjová, A. Ježíková, P. Makovický, M. Mokáň

Vnitr Lek 2006, 52(6):640-644  

Uremia, the result of renal failure, is a serious clinical problem. Rising azotemia during gravidity significantly increases perinatal morbidity and mortality. This study presents the case of 34 years old patient with 27-year medical history of diabetes mellitus type 1 with diabetic nephropathy and chronic renal insufficiency. The patient got pregnant in the stage of preterminal renal failure. During the first trimester, she showed hypertension and proteinuria. In her 25th week of pregnancy, she was hospitalized with progressive proteinuria, almost uncontrollable hypertension and increased azotemia. Intensive conservative therapy led to a slight decrease...

Post-transplantation lymphoproliferation in patients with intensive immunosuppression

H. Vavřinová, O. Viklický, J. Lácha, D. Housa, L. Hošková, V. Teplan

Vnitr Lek 2006, 52(6):645-648  

Organ allograft recipients are at higher risk for malignancies development. This risk is known to be different in different types of tumours. Skin cancers and lymphoproliferative disorders have been described to be ones the most frequent (comprising 15-25 % of all malignancies). Here, we present the case of expansive formation localized near the renal allograft in patient, whose native kidneys failed as a consequence of long-term cyclosporine A therapy after orthotopic heart transplantation. The maintenance immunosuppression consisted of combination of cyclosporine A, mycophenolate mofetil and steroids. The expansion offside of transplanted kidney...

Teplan V et al. Praktická nefrologie. 2., zcela přepracované a doplněné vydání. Praha: Grada Publishing 2006. 496 stran. ISBN 80-247-1122-2

Václav Monhart

Vnitr Lek 2006, 52(6):651-652  

Benáková N. Ekzémy a dermatitidy. Praha: Maxdorf 2006. 125 stran. ISBN-80-7345-078-X

Vladimír Vašků

Vnitr Lek 2006, 52(6):652  

XXV. Dny mladých internistů v Martině

P. Horák

Vnitr Lek 2006, 52(6):653  

XIII. medzinárodný kongres pre metabolizmus a výživu pri chorobách obličiek, 28. februára až 4. marca 2006, Mérida, Yucatán (Mexiko)

M. Mydlík

Vnitr Lek 2006, 52(6):654-655